PHAT - Phathom Pharma to initiate vonoprazan development in reflux disease study

Phathom Pharmaceuticals ([[PHAT]] +4.8%) plans to expand its vonoprazan development program into non-erosive reflux disease ((NERD)), a subcategory of gastroesophageal reflux disease and is characterized by reflux-related symptoms in the absence of esophageal mucosal erosions.As a next step in its NERD development program, Phathom anticipates initiating a Phase 2 trial in mid-2021 to evaluate various doses of vonoprazan as an on-demand therapy for patients with NERD.Last month, completed enrollment in PHALCON-EE, a pivotal trial evaluating vonoprazan for both the healing and maintenance of healing of erosive esophagitis as well as the relief of heartburn. Topline results are expected in the 1H of 2021Enrollment is currently ongoing for PHALCON-HP, another pivotal trial evaluating vonoprazan in combination with antibiotics for the eradication of H. pylori infection. Enrollment is expected to complete in January next year with topline results in Q2 of 2021.The company will hosting a virtual Investor Day today, beginning at 1

For further details see:

Phathom Pharma to initiate vonoprazan development in reflux disease study